ImmunoPrecise Antibodies (IPA) said Thursday it has entered into a strategic partnership with an unnamed biotechnology company to discover and develop antibody-drug conjugates and bispecific antibodies to treat cancer.
The company said the agreement is valued at $8 million and can be increased to $10 million based on program progression. It will last 18 to 24 months, the company added.
ImmunoPrecise said the partnership will use its B-cell Select platform and artificial intelligence.
Shares of ImmunoPrecise surged past 23% in Thursday's premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。